AstraZeneca PLC (AZN) operating KPIs
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
KPIs
Operating metrics that drive AstraZeneca's business · fiscal year ends December 31 (calendar fiscal year; FY2025 ended December 31, 2025; Q2 2026 ended June 30, 2026)
The chart is empty. Tick the box next to any metric in the table below to plot it — tick several to compare them on one chart.
| Add to chart | Metric | Q2 2026 2026-06-30 | Q1 2026 2026-03-31 | Q4 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 | Q1 2025 2025-03-31 | Q4 2024 2024-12-31 | Q3 2024 2024-09-30 | Q2 2024 2024-06-30 | Q1 2024 2024-03-31 | Q4 2023 2023-12-31 | Q3 2023 2023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total revenue ($M)($M)7 | 15,384 | 15,288 | 15,503 | 15,191 | 14,457 | 13,588 | 14,891 | 13,565 | 12,938 | 12,679 | 12,024 | 11,492 | |
Product sales ($M)($M) | 14,510 | 14,386 | 14,538 | 14,365 | 13,795 | 12,875 | 13,362 | 12,947 | 12,452 | 12,177 | 11,323 | 11,018 | |
Alliance revenue ($M)($M)6 | 874 | 825 | 959 | 815 | 654 | 639 | 714 | 559 | 482 | 457 | 424 | 377 | |
Enhertu (Daiichi Sankyo alliance) revenue ($M)($M) | 550 | 508 | 507 | 457 | 436 | 392 | 361 | 344 | 339 | 281 | 266 | ||
Tezspire (Amgen alliance) revenue ($M)($M) | 218 | 154 | 220 | 168 | 155 | 133 | 123 | 104 | 77 | 80 | 74 | ||
Beyfortus (Sanofi / Sobi alliance) revenue ($M)($M) | 32 | 116 | 170 | 142 | 27 | 161 | 49 | 7 | 20 | 41 | |||
Datroway (Daiichi Sankyo alliance) revenue ($M)($M) | 51 | 42 | 39 | 24 | 10 | ||||||||
Other royalty income ($M)($M) | 22 | 29 | 22 | 24 | 21 | 18 | |||||||
Other alliance revenue ($M)($M) | 1 | 1 | 1 | 24 | 26 | 4 | 26 | 27 | 21 | 1 | 19 | ||
Collaboration revenue ($M)($M) | 0 | 77 | 6 | 11 | 8 | 74 | 815 | 59 | 4 | 45 | 277 | 97 | |
United States (US) — Total revenue ($M)($M)3 | 6,686 | 6,205 | 6,932 | 6,548 | 6,323 | 5,646 | 6,532 | 6,008 | 5,571 | 5,124 | 5,101 | 4,859 | |
United States (US) — Share of total revenue (%)(%) | 43.0% | 41.0% | 45.0% | 43.0% | 44.0% | 42.0% | 44.0% | 44.0% | 43.0% | 40.0% | 42.0% | 42.0% | |
United States (US) — Revenue YoY actual (%)(%) | 6.0% | 10.0% | 6.0% | 9.0% | 13.0% | 10.0% | 28.0% | 23.0% | 17.0% | 19.0% | 7.0% | 5.0% | |
United States (US) — Revenue YoY at constant exchange rates / CER (%)(%) | 6.0% | 10.0% | 6.0% | 9.0% | 14.0% | 10.0% | 28.0% | 23.0% | 17.0% | 19.0% | 6.0% | 4.0% | |
Emerging Markets — Total revenue ($M)($M)5 | 3,921 | 4,398 | 3,646 | 3,960 | 3,754 | 3,943 | 3,134 | 3,423 | 3,386 | 3,732 | 2,783 | 2,964 | |
Emerging Markets — Share of total revenue (%)(%) | 25.0% | 29.0% | 24.0% | 26.0% | 26.0% | 29.0% | 21.0% | 25.0% | 26.0% | 29.0% | 23.0% | 26.0% | |
Emerging Markets — Revenue YoY actual (%)(%) | 4.0% | 12.0% | 16.0% | 16.0% | 11.0% | 6.0% | 13.0% | 15.0% | 9.0% | 18.0% | 2.0% | 4.0% | |
Emerging Markets — Revenue YoY at constant exchange rates / CER (%)(%) | 0.0% | 6.0% | 14.0% | 15.0% | 13.0% | 12.0% | 19.0% | 23.0% | 18.0% | 26.0% | 8.0% | 12.0% | |
China — Total revenue ($M)($M)3 | 1,587 | 1,923 | 1,375 | 1,764 | 1,710 | 1,805 | 1,364 | 1,671 | 1,630 | 1,748 | 1,382 | 1,452 | |
China — Share of total revenue (%)(%) | 10.0% | 13.0% | 9.0% | 12.0% | 12.0% | 13.0% | 9.0% | 12.0% | 13.0% | 14.0% | 11.0% | 13.0% | |
China — Revenue YoY actual (%)(%) | -7.0% | 7.0% | 1.0% | 6.0% | 5.0% | 3.0% | -1.0% | 15.0% | 13.0% | 9.0% | 16.0% | -6.0% | |
China — Revenue YoY at constant exchange rates / CER (%)(%) | -13.0% | 2.0% | 1.0% | 5.0% | 5.0% | 5.0% | -3.0% | 15.0% | 18.0% | 13.0% | 16.0% | 1.0% | |
Emerging Markets excluding China — Total revenue ($M)($M)3 | 2,334 | 2,475 | 2,271 | 2,196 | 2,043 | 2,138 | 1,770 | 1,752 | 1,756 | 1,984 | 1,401 | 1,513 | |
Emerging Markets excluding China — Share of total revenue (%)(%) | 15.0% | 16.0% | 15.0% | 14.0% | 14.0% | 16.0% | 12.0% | 13.0% | 14.0% | 16.0% | 12.0% | 13.0% | |
Emerging Markets excluding China — Revenue YoY actual (%)(%) | 14.0% | 16.0% | 28.0% | 25.0% | 16.0% | 8.0% | 26.0% | 16.0% | 5.0% | 27.0% | -9.0% | 15.0% | |
Emerging Markets excluding China — Revenue YoY at constant exchange rates / CER (%)(%) | 11.0% | 9.0% | 24.0% | 25.0% | 21.0% | 17.0% | 42.0% | 31.0% | 18.0% | 40.0% | 2.0% | 25.0% | |
Europe — Total revenue ($M)($M)3 | 3,417 | 3,405 | 3,579 | 3,334 | 3,066 | 2,759 | 3,948 | 2,875 | 2,732 | 2,634 | 2,880 | 2,392 | |
Europe — Share of total revenue (%)(%) | 22.0% | 22.0% | 23.0% | 22.0% | 21.0% | 20.0% | 27.0% | 21.0% | 21.0% | 21.0% | 24.0% | 21.0% | |
Europe — Revenue YoY actual (%)(%) | 11.0% | 23.0% | -9.0% | 16.0% | 12.0% | 5.0% | 37.0% | 22.0% | 24.0% | 22.0% | 25.0% | 16.0% | |
Europe — Revenue YoY at constant exchange rates / CER (%)(%) | 7.0% | 9.0% | -15.0% | 10.0% | 8.0% | 9.0% | 35.0% | 22.0% | 24.0% | 19.0% | 17.0% | 9.0% | |
Established Rest of World (Japan, Canada, Australia & New Zealand) — Total revenue ($M)($M)3 | 1,361 | 1,280 | 1,345 | 1,349 | 1,315 | 1,239 | 1,277 | 1,260 | 1,249 | 1,189 | 1,259 | 1,276 | |
Established Rest of World (Japan, Canada, Australia & New Zealand) — Share of total revenue (%)(%) | 9.0% | 8.0% | 9.0% | 9.0% | 9.0% | 9.0% | 9.0% | 9.0% | 10.0% | 9.0% | 10.0% | 11.0% | |
Established Rest of World (Japan, Canada, Australia & New Zealand) — Revenue YoY actual (%)(%) | 4.0% | 3.0% | 5.0% | 7.0% | 5.0% | 4.0% | 1.0% | -1.0% | -5.0% | -5.0% | -9.0% | -10.0% | |
Established Rest of World (Japan, Canada, Australia & New Zealand) — Revenue YoY at constant exchange rates / CER (%)(%) | 8.0% | 2.0% | 7.0% | 5.0% | 2.0% | 9.0% | 2.0% | 4.0% | 6.0% | 2.0% | -6.0% | -6.0% | |
Oncology — Worldwide product sales ($M)($M)16 | 6,713 | 6,236 | 6,470 | 6,143 | 5,854 | 5,231 | 5,341 | 5,197 | 4,976 | 4,760 | 4,453 | 4,389 | |
Oncology — Worldwide YoY actual (%)(%) | 15.0% | 19.0% | 21.0% | 18.0% | 18.0% | 10.0% | 20.0% | 18.0% | 14.0% | 21.0% | 19.0% | 16.0% | |
Oncology — Worldwide YoY CER (%)(%) | 13.0% | 15.0% | 19.0% | 17.0% | 17.0% | 13.0% | 22.0% | 21.0% | 18.0% | 24.0% | 19.0% | 17.0% | |
Oncology — US product sales ($M)($M)1 | 3,163 | 2,788 | 3,128 | 2,893 | 2,770 | 2,397 | 2,640 | 2,484 | 2,302 | 2,084 | 2,067 | 1,986 | |
Oncology — US YoY (%)(%) | 14.0% | 16.0% | 18.0% | 16.0% | 20.0% | 15.0% | 28.0% | 25.0% | 17.0% | 22.0% | 16.0% | 16.0% | |
Oncology — Emerging Markets product sales ($M)($M)2 | 1,522 | 1,521 | 1,342 | 1,380 | 1,310 | 1,318 | 1,057 | 1,145 | 1,098 | 1,202 | 904 | 971 | |
Oncology — Emerging Markets YoY actual (%)(%) | 16.0% | 15.0% | 27.0% | 21.0% | 19.0% | 10.0% | 17.0% | 18.0% | 11.0% | 24.0% | 11.0% | 4.0% | |
Oncology — Emerging Markets YoY CER (%)(%) | 12.0% | 10.0% | 25.0% | 21.0% | 22.0% | 16.0% | 27.0% | 28.0% | 22.0% | 33.0% | 18.0% | 13.0% | |
Oncology — Europe product sales ($M)($M)2 | 1,408 | 1,378 | 1,381 | 1,284 | 1,183 | 1,032 | 1,082 | 1,032 | 1,015 | 953 | 903 | 849 | |
Oncology — Europe YoY actual (%)(%) | 19.0% | 34.0% | 28.0% | 24.0% | 17.0% | 8.0% | 20.0% | 22.0% | 24.0% | 26.0% | 31.0% | 22.0% | |
Oncology — Europe YoY CER (%)(%) | 14.0% | 18.0% | 19.0% | 17.0% | 12.0% | 12.0% | 18.0% | 22.0% | 24.0% | 23.0% | 22.0% | 15.0% | |
Oncology — Established RoW product sales ($M)($M)2 | 620 | 549 | 619 | 586 | 591 | 484 | 562 | 536 | 561 | 521 | 579 | 583 | |
Oncology — Established RoW YoY actual (%)(%) | 5.0% | 13.0% | 10.0% | 9.0% | 5.0% | -7.0% | -3.0% | -8.0% | -9.0% | 6.0% | 28.0% | 28.0% | |
Oncology — Established RoW YoY CER (%)(%) | 10.0% | 12.0% | 12.0% | 7.0% | 2.0% | -2.0% | -3.0% | -3.0% | 2.0% | 16.0% | 32.0% | 35.0% | |
Tagrisso (osimertinib) — Worldwide product sales ($M)($M)6 | 1,941 | 1,833 | 1,902 | 1,864 | 1,810 | 1,679 | 1,703 | 1,674 | 1,608 | 1,595 | 1,419 | 1,465 | |
Imfinzi (durvalumab) — Worldwide product sales ($M)($M)6 | 1,854 | 1,694 | 1,747 | 1,601 | 1,455 | 1,261 | 1,254 | 1,203 | 1,147 | 1,113 | 1,135 | 1,126 | |
Calquence (acalabrutinib) — Worldwide product sales ($M)($M)6 | 1,022 | 923 | 967 | 916 | 872 | 762 | 808 | 813 | 790 | 718 | 675 | 654 | |
Lynparza (olaparib) — Worldwide product sales ($M)($M)6 | 829 | 781 | 878 | 837 | 838 | 726 | 844 | 778 | 744 | 705 | 741 | 702 | |
Enhertu (trastuzumab deruxtecan — direct product sales) — Worldwide product sales ($M)($M)6 | 338 | 324 | 292 | 257 | 230 | 198 | 148 | 148 | 127 | 122 | 83 | 73 | |
Truqap (capivasertib) — Worldwide product sales ($M)($M)6 | 233 | 198 | 233 | 193 | 170 | 132 | 163 | 125 | 92 | 50 | 6 | ||
Zoladex (goserelin) — Worldwide product sales ($M)($M)6 | 304 | 304 | 254 | 285 | 284 | 283 | 242 | 268 | 273 | 276 | 254 | 239 | |
Imjudo (tremelimumab) — Worldwide product sales ($M)($M)6 | 83 | 77 | 93 | 84 | 89 | 80 | 73 | 72 | 74 | 62 | |||
Datroway (datopotamab deruxtecan — direct product sales) — Worldwide product sales ($M)($M)4 | 4 | 1 | 1 | ||||||||||
Other Oncology medicines — Worldwide product sales ($M)($M)6 | 102 | 101 | 103 | 106 | 106 | 110 | 97 | 106 | 109 | 107 | 50 | 54 | |
Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M)($M)14 | 2,771 | 3,240 | 3,044 | 3,214 | 3,261 | 3,245 | 3,132 | 3,152 | 3,153 | 3,012 | 2,698 | 2,683 | |
Cardiovascular, Renal & Metabolism (CVRM) — Worldwide YoY actual (%)(%) | -15.0% | 0.0% | -3.0% | 2.0% | 3.0% | 8.0% | 16.0% | 17.0% | 18.0% | 19.0% | 18.0% | 14.0% | |
Cardiovascular, Renal & Metabolism (CVRM) — Worldwide YoY CER (%)(%) | -18.0% | -6.0% | -6.0% | 0.0% | 3.0% | 12.0% | 17.0% | 20.0% | 22.0% | 22.0% | 18.0% | 16.0% | |
Cardiovascular, Renal & Metabolism (CVRM) — US product sales ($M)($M)1 | 375 | 593 | 709 | 662 | 665 | 687 | 853 | 739 | 735 | 748 | 780 | 690 | |
Cardiovascular, Renal & Metabolism (CVRM) — US YoY (%)(%) | -44.0% | -14.0% | -17.0% | -10.0% | -10.0% | -8.0% | 9.0% | 7.0% | 11.0% | 20.0% | 12.0% | 9.0% | |
Cardiovascular, Renal & Metabolism (CVRM) — Emerging Markets product sales ($M)($M)2 | 1,346 | 1,653 | 1,270 | 1,559 | 1,512 | 1,552 | 1,193 | 1,396 | 1,384 | 1,365 | 1,078 | 1,161 | |
Cardiovascular, Renal & Metabolism (CVRM) — Emerging Markets YoY actual (%)(%) | -11.0% | 7.0% | 6.0% | 12.0% | 9.0% | 14.0% | 11.0% | 20.0% | 17.0% | 17.0% | 15.0% | 7.0% | |
Cardiovascular, Renal & Metabolism (CVRM) — Emerging Markets YoY CER (%)(%) | -15.0% | 0.0% | 4.0% | 11.0% | 11.0% | 20.0% | 14.0% | 25.0% | 24.0% | 24.0% | 19.0% | 15.0% | |
Cardiovascular, Renal & Metabolism (CVRM) — Europe product sales ($M)($M)2 | 887 | 868 | 895 | 806 | 889 | 807 | 886 | 826 | 843 | 716 | 679 | 657 | |
Cardiovascular, Renal & Metabolism (CVRM) — Europe YoY actual (%)(%) | 0.0% | 8.0% | 1.0% | -2.0% | 5.0% | 13.0% | 31.0% | 26.0% | 38.0% | 29.0% | 38.0% | 40.0% | |
Cardiovascular, Renal & Metabolism (CVRM) — Europe YoY CER (%)(%) | -4.0% | -5.0% | -6.0% | -8.0% | 1.0% | 17.0% | 28.0% | 26.0% | 38.0% | 26.0% | 28.0% | 32.0% | |
Cardiovascular, Renal & Metabolism (CVRM) — Established RoW product sales ($M)($M)2 | 163 | 126 | 170 | 187 | 195 | 199 | 200 | 191 | 191 | 183 | 161 | 175 | |
Cardiovascular, Renal & Metabolism (CVRM) — Established RoW YoY actual (%)(%) | -16.0% | -37.0% | -15.0% | -2.0% | 2.0% | 9.0% | 24.0% | 9.0% | -14.0% | -2.0% | 5.0% | 6.0% | |
Cardiovascular, Renal & Metabolism (CVRM) — Established RoW YoY CER (%)(%) | -12.0% | -38.0% | -13.0% | -4.0% | -2.0% | 13.0% | 24.0% | 14.0% | -3.0% | 7.0% | 8.0% | 10.0% | |
Farxiga / Forxiga (dapagliflozin) — Worldwide product sales ($M)($M)6 | 1,804 | 2,193 | 2,059 | 2,134 | 2,150 | 2,057 | 1,933 | 1,938 | 1,940 | 1,845 | 1,606 | 1,554 | |
Lokelma (sodium zirconium cyclosilicate) — Worldwide product sales ($M)($M)6 | 221 | 199 | 181 | 189 | 175 | 153 | 150 | 143 | 136 | 114 | 112 | 102 | |
Brilinta / Brilique (ticagrelor) — Worldwide product sales ($M)($M)6 | 80 | 105 | 158 | 146 | 215 | 305 | 341 | 327 | 342 | 323 | 329 | 331 | |
Crestor (rosuvastatin) — Worldwide product sales ($M)($M)6 | 331 | 354 | 275 | 305 | 319 | 316 | 261 | 304 | 292 | 297 | 247 | 275 | |
Seloken / Toprol-XL (metoprolol) — Worldwide product sales ($M)($M)6 | 157 | 180 | 139 | 160 | 148 | 161 | 140 | 150 | 150 | 165 | 144 | 153 | |
Roxadustat (evrenzo) — Worldwide product sales ($M)($M)6 | 14 | 43 | 47 | 77 | 72 | 78 | 74 | 93 | 88 | 75 | 63 | 74 | |
Wainua (eplontersen) — Worldwide product sales ($M)($M)6 | 70 | 51 | 69 | 59 | 44 | 39 | 42 | 23 | 16 | 5 | |||
Other CVRM medicines — Worldwide product sales ($M)($M)6 | 91 | 115 | 116 | 144 | 138 | 136 | 132 | 120 | 130 | 141 | 58 | 66 | |
Respiratory & Immunology (R&I) — Worldwide product sales ($M)($M)14 | 2,207 | 2,150 | 2,147 | 2,085 | 1,988 | 1,947 | 1,985 | 1,830 | 1,797 | 1,804 | 1,590 | 1,451 | |
Respiratory & Immunology (R&I) — Worldwide YoY actual (%)(%) | 11.0% | 10.0% | 8.0% | 14.0% | 11.0% | 8.0% | 25.0% | 26.0% | 21.0% | 14.0% | 10.0% | 2.0% | |
Respiratory & Immunology (R&I) — Worldwide YoY CER (%)(%) | 9.0% | 6.0% | 6.0% | 12.0% | 10.0% | 11.0% | 26.0% | 28.0% | 24.0% | 16.0% | 10.0% | 3.0% | |
Respiratory & Immunology (R&I) — US product sales ($M)($M)1 | 982 | 880 | 984 | 1,013 | 977 | 865 | 996 | 852 | 830 | 737 | 647 | 609 | |
Respiratory & Immunology (R&I) — US YoY (%)(%) | 0.0% | 2.0% | -1.0% | 19.0% | 18.0% | 17.0% | 54.0% | 40.0% | 23.0% | 19.0% | -6.0% | -8.0% | |
Respiratory & Immunology (R&I) — Emerging Markets product sales ($M)($M)2 | 490 | 565 | 468 | 445 | 381 | 529 | 408 | 457 | 444 | 588 | 456 | 422 | |
Respiratory & Immunology (R&I) — Emerging Markets YoY actual (%)(%) | 29.0% | 7.0% | 15.0% | -3.0% | -14.0% | -10.0% | -11.0% | 8.0% | 23.0% | 10.0% | 34.0% | 14.0% | |
Respiratory & Immunology (R&I) — Emerging Markets YoY CER (%)(%) | 24.0% | 2.0% | 12.0% | -3.0% | -13.0% | -6.0% | -7.0% | 14.0% | 34.0% | 16.0% | 41.0% | 23.0% | |
Respiratory & Immunology (R&I) — Europe product sales ($M)($M)2 | 509 | 498 | 477 | 425 | 422 | 378 | 391 | 346 | 350 | 330 | 317 | 266 | |
Respiratory & Immunology (R&I) — Europe YoY actual (%)(%) | 21.0% | 32.0% | 22.0% | 23.0% | 21.0% | 14.0% | 23.0% | 30.0% | 21.0% | 13.0% | 22.0% | 9.0% | |
Respiratory & Immunology (R&I) — Europe YoY CER (%)(%) | 16.0% | 17.0% | 14.0% | 16.0% | 16.0% | 19.0% | 21.0% | 30.0% | 21.0% | 11.0% | 14.0% | 2.0% | |
Respiratory & Immunology (R&I) — Established RoW product sales ($M)($M)2 | 226 | 207 | 218 | 202 | 208 | 175 | 190 | 175 | 173 | 149 | 170 | 154 | |
Respiratory & Immunology (R&I) — Established RoW YoY actual (%)(%) | 9.0% | 19.0% | 15.0% | 16.0% | 20.0% | 17.0% | 12.0% | 13.0% | 8.0% | 6.0% | 10.0% | 3.0% | |
Respiratory & Immunology (R&I) — Established RoW YoY CER (%)(%) | 11.0% | 15.0% | 17.0% | 15.0% | 19.0% | 24.0% | 12.0% | 18.0% | 14.0% | 11.0% | 12.0% | 7.0% | |
Fasenra (benralizumab) — Worldwide product sales ($M)($M)6 | 570 | 483 | 530 | 530 | 502 | 418 | 471 | 436 | 423 | 358 | 420 | 389 | |
Breztri Aerosphere (budesonide/glycopyrronium/formoterol) — Worldwide product sales ($M)($M)6 | 346 | 353 | 294 | 323 | 283 | 300 | 257 | 266 | 235 | 219 | 199 | 171 | |
Symbicort (budesonide/formoterol) — Worldwide product sales ($M)($M)6 | 671 | 747 | 704 | 742 | 715 | 723 | 684 | 705 | 722 | 769 | 520 | 555 | |
Tezspire (tezepelumab — direct product sales) — Worldwide product sales ($M)($M)6 | 172 | 149 | 141 | 119 | 112 | 87 | 80 | 68 | 57 | 43 | 35 | 21 | |
Saphnelo (anifrolumab) — Worldwide product sales ($M)($M)6 | 209 | 171 | 203 | 180 | 167 | 136 | 147 | 124 | 112 | 91 | 89 | 76 | |
Airsupra (albuterol/budesonide) — Worldwide product sales ($M)($M)4 | 50 | 37 | 51 | 45 | 42 | 28 | 25 | 21 | 14 | 7 | |||
Pulmicort (budesonide) — Worldwide product sales ($M)($M)6 | 120 | 149 | 161 | 93 | 106 | 158 | 164 | 138 | 155 | 224 | 219 | 148 | |
Other Respiratory & Immunology medicines — Worldwide product sales ($M)($M)6 | 69 | 61 | 63 | 53 | 61 | 97 | 157 | 72 | 79 | 93 | 80 | 67 | |
Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M)($M)9 | 99 | 90 | 272 | 274 | 157 | 143 | 378 | 355 | 112 | 212 | 345 | 224 | |
Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide YoY actual (%)(%) | -37.0% | -37.0% | -28.0% | -23.0% | 40.0% | -32.0% | 10.0% | 59.0% | 28.0% | -40.0% | -69.0% | -74.0% | |
Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide YoY CER (%)(%) | -38.0% | -41.0% | -30.0% | -24.0% | 42.0% | -30.0% | 8.0% | 61.0% | 42.0% | -40.0% | -70.0% | -74.0% | |
Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — US product sales ($M)($M)1 | 35 | 23 | 54 | 54 | 73 | 27 | 80 | 145 | 28 | 27 | 59 | 15 | |
Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — US YoY (%)(%) | -52.0% | -15.0% | -32.0% | -63.0% | 2.0% | 35.0% | -74.0% | -95.0% | |||||
Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Emerging Markets product sales ($M)($M)2 | 31 | 40 | 59 | 40 | 38 | 83 | 45 | 37 | 41 | 90 | 31 | 32 | |
Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Emerging Markets YoY actual (%)(%) | -18.0% | -52.0% | 32.0% | 7.0% | -6.0% | -8.0% | 46.0% | 18.0% | -10.0% | -13.0% | -90.0% | -76.0% | |
Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Emerging Markets YoY CER (%)(%) | -24.0% | -55.0% | 26.0% | 7.0% | -1.0% | -3.0% | 58.0% | 37.0% | 4.0% | -12.0% | -90.0% | -75.0% | |
Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Europe product sales ($M)($M)2 | 9 | 16 | 153 | 152 | 24 | 26 | 219 | 108 | 7 | 74 | 195 | 122 | |
Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Europe YoY actual (%)(%) | -62.0% | -40.0% | -30.0% | 41.0% | -65.0% | 12.0% | 23.0% | -55.0% | -27.0% | -42.0% | -33.0% | ||
Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Europe YoY CER (%)(%) | -64.0% | -47.0% | -33.0% | 37.0% | -64.0% | 9.0% | 20.0% | -53.0% | -26.0% | -45.0% | -35.0% | ||
Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Established RoW product sales ($M)($M)2 | 24 | 11 | 6 | 28 | 22 | 7 | 34 | 65 | 36 | 21 | 60 | 55 | |
Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Established RoW YoY actual (%)(%) | 7.0% | 67.0% | -82.0% | -57.0% | -39.0% | -67.0% | -43.0% | 18.0% | 36.0% | -87.0% | -76.0% | -78.0% | |
Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Established RoW YoY CER (%)(%) | 6.0% | 55.0% | -82.0% | -57.0% | -40.0% | -67.0% | -44.0% | 23.0% | 55.0% | -86.0% | -75.0% | -77.0% | |
Beyfortus (nirsevimab — direct product sales) — Worldwide product sales ($M)($M)6 | 47 | 24 | 59 | 94 | 98 | 30 | 130 | 134 | 28 | 26 | 54 | 50 | |
FluMist / Fluenz (influenza vaccine) — Worldwide product sales ($M)($M)6 | 18 | 8 | 140 | 122 | 10 | 0 | 149 | 100 | 2 | 7 | 138 | 75 | |
Other Vaccines & Immune Therapies — Worldwide product sales ($M)($M)6 | 34 | 58 | 1 | 0 | 0 | 1 | -2 | 0 | 0 | 6 | |||
Rare Disease (Alexion) — Worldwide product sales ($M)($M)11 | 2,490 | 2,420 | 2,374 | 2,416 | 2,294 | 2,042 | 2,277 | 2,148 | 2,147 | 2,096 | 1,971 | 1,974 | |
Rare Disease (Alexion) — Worldwide YoY actual (%)(%) | 9.0% | 19.0% | 4.0% | 12.0% | 7.0% | -3.0% | 16.0% | 9.0% | 10.0% | 12.0% | 9.0% | 13.0% | |
Rare Disease (Alexion) — Worldwide YoY CER (%)(%) | 8.0% | 15.0% | 3.0% | 11.0% | 7.0% | 0.0% | 17.0% | 11.0% | 14.0% | 16.0% | 9.0% | 14.0% | |
Rare Disease (Alexion) — US product sales ($M)($M)1 | 1,452 | 1,372 | 1,424 | 1,415 | 1,346 | 1,237 | 1,421 | 1,325 | 1,311 | 1,207 | 1,232 | 1,179 | |
Rare Disease (Alexion) — US YoY (%)(%) | 8.0% | 11.0% | 0.0% | 7.0% | 3.0% | 3.0% | 15.0% | 12.0% | 10.0% | 10.0% | 7.0% | 9.0% | |
Rare Disease (Alexion) — Emerging Markets product sales ($M)($M)2 | 305 | 347 | 248 | 307 | 278 | 205 | 221 | 174 | 203 | 251 | 136 | 163 | |
Rare Disease (Alexion) — Emerging Markets YoY actual (%)(%) | 10.0% | 69.0% | 12.0% | 76.0% | 37.0% | -18.0% | 63.0% | 7.0% | 35.0% | 45.0% | 18.0% | 49.0% | |
Rare Disease (Alexion) — Emerging Markets YoY CER (%)(%) | 6.0% | 57.0% | 10.0% | 73.0% | 48.0% | -10.0% | 84.0% | 29.0% | 67.0% | 73.0% | 46.0% | 70.0% | |
Rare Disease (Alexion) — Europe product sales ($M)($M)2 | 442 | 431 | 422 | 410 | 412 | 360 | 379 | 395 | 392 | 401 | 364 | 397 | |
Rare Disease (Alexion) — Europe YoY actual (%)(%) | 7.0% | 20.0% | 11.0% | 4.0% | 5.0% | -10.0% | 4.0% | 0.0% | 3.0% | 4.0% | 4.0% | 15.0% | |
Rare Disease (Alexion) — Europe YoY CER (%)(%) | 3.0% | 6.0% | 4.0% | -2.0% | 1.0% | -7.0% | 2.0% | 0.0% | 3.0% | 1.0% | -3.0% | 8.0% | |
Rare Disease (Alexion) — Established RoW product sales ($M)($M)2 | 291 | 270 | 280 | 284 | 258 | 240 | 256 | 254 | 241 | 237 | 239 | 235 | |
Rare Disease (Alexion) — Established RoW YoY actual (%)(%) | 13.0% | 13.0% | 9.0% | 12.0% | 7.0% | 1.0% | 7.0% | 8.0% | 7.0% | 12.0% | 18.0% | 16.0% | |
Rare Disease (Alexion) — Established RoW YoY CER (%)(%) | 20.0% | 13.0% | 11.0% | 9.0% | 2.0% | 6.0% | 8.0% | 14.0% | 18.0% | 21.0% | 22.0% | 22.0% | |
Ultomiris (ravulizumab) — Worldwide product sales ($M)($M)6 | 1,314 | 1,270 | 1,265 | 1,225 | 1,177 | 1,050 | 1,089 | 1,031 | 946 | 859 | 825 | 777 | |
Soliris (eculizumab) — Worldwide product sales ($M)($M)6 | 389 | 389 | 401 | 462 | 530 | 444 | 543 | 606 | 700 | 739 | 715 | 781 | |
Strensiq (asfotase alfa) — Worldwide product sales ($M)($M)6 | 536 | 517 | 490 | 441 | 395 | 352 | 420 | 343 | 340 | 313 | 305 | 285 | |
Koselugo (selumetinib) — Worldwide product sales ($M)($M)6 | 177 | 170 | 163 | 224 | 137 | 138 | 165 | 119 | 114 | 132 | 85 | 87 | |
Other Rare Disease medicines — Worldwide product sales ($M)($M)6 | 74 | 74 | 55 | 64 | 55 | 58 | |||||||
Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M)($M)6 | 230 | 250 | 231 | 233 | 241 | 267 | 249 | 265 | 267 | 293 | 266 | 297 | |
Other Medicines (Established / Legacy Brands) — Worldwide YoY actual (%)(%) | -4.0% | -7.0% | -7.0% | -12.0% | -10.0% | -9.0% | -6.0% | -11.0% | -11.0% | -6.0% | -30.0% | -27.0% | |
Other Medicines (Established / Legacy Brands) — Worldwide YoY CER (%)(%) | -6.0% | -9.0% | -7.0% | -12.0% | -9.0% | -5.0% | -4.0% | -7.0% | -5.0% | 1.0% | -28.0% | -22.0% | |
Other Medicines (Established / Legacy Brands) — US product sales ($M)($M)1 | 19 | 23 | 14 | 9 | 21 | 19 | 24 | 35 | 28 | 24 | 29 | 36 | |
Other Medicines (Established / Legacy Brands) — US YoY (%)(%) | -9.0% | 22.0% | -41.0% | -73.0% | -26.0% | -20.0% | -18.0% | -3.0% | -13.0% | -33.0% | -9.0% | -3.0% | |
Other Medicines (Established / Legacy Brands) — Emerging Markets product sales ($M)($M)2 | 166 | 192 | 168 | 172 | 186 | 206 | 171 | 179 | 179 | 206 | 151 | 190 | |
Other Medicines (Established / Legacy Brands) — Emerging Markets YoY actual (%)(%) | -10.0% | -7.0% | -2.0% | -4.0% | 4.0% | 0.0% | 14.0% | -6.0% | -3.0% | 0.0% | -16.0% | -11.0% | |
Other Medicines (Established / Legacy Brands) — Emerging Markets YoY CER (%)(%) | -13.0% | -9.0% | -1.0% | -3.0% | 5.0% | 4.0% | 17.0% | 0.0% | 5.0% | 11.0% | -13.0% | -4.0% | |
Other Medicines (Established / Legacy Brands) — Europe product sales ($M)($M)2 | 25 | 15 | 25 | 23 | 16 | 19 | 28 | 22 | 24 | 29 | 38 | 19 | |
Other Medicines (Established / Legacy Brands) — Europe YoY actual (%)(%) | 52.0% | -23.0% | -10.0% | 4.0% | -32.0% | -35.0% | -27.0% | 18.0% | -7.0% | 31.0% | 36.0% | -32.0% | |
Other Medicines (Established / Legacy Brands) — Europe YoY CER (%)(%) | 51.0% | -30.0% | -14.0% | 3.0% | -38.0% | -30.0% | -28.0% | 16.0% | -7.0% | 30.0% | 34.0% | -34.0% | |
Other Medicines (Established / Legacy Brands) — Established RoW product sales ($M)($M)2 | 20 | 20 | 24 | 29 | 18 | 23 | 26 | 29 | 36 | 34 | 48 | 52 | |
Other Medicines (Established / Legacy Brands) — Established RoW YoY actual (%)(%) | 12.0% | -15.0% | -8.0% | 0.0% | -50.0% | -32.0% | -46.0% | -45.0% | -38.0% | -31.0% | -66.0% | -59.0% | |
Other Medicines (Established / Legacy Brands) — Established RoW YoY CER (%)(%) | 14.0% | -17.0% | -6.0% | -4.0% | -50.0% | -29.0% | -45.0% | -41.0% | -32.0% | -25.0% | -65.0% | -56.0% | |
Total projects in clinical development pipeline (count)3 | 183 | 186 | 197 | 198 | 196 | 194 | 191 | 199 | 189 | 182 | 178 | ||
Phase II & Phase III NME or major LCM projects in pipeline (count) | 116 | 118 | 125 | 122 | 132 | 132 | 130 | 139 | 131 | 123 | 123 | ||
New Molecular Entities (NMEs) in late-stage pipeline (count) | 21 | 21 | 20 | 20 | 19 | 18 | 19 | 21 | 20 | 19 | 17 | ||
Regulatory approvals in major markets — US, EU, China, Japan (count) | 15 | 14 | 7 | 12 | 8 | 16 | 6 | 9 | 7 | 9 | |||
Core gross profit ($M)($M)5 | 12,863 | 12,624 | 12,334 | 12,417 | 11,914 | 11,365 | 12,089 | 11,112 | 10,780 | 10,491 | 9,738 | 9,444 | |
Core gross margin (% of product sales)(%) | 84.0% | 83.0% | 80.0% | 82.0% | 82.0% | 84.0% | |||||||
Core gross profit YoY actual (%)(%) | 8.0% | 11.0% | 2.0% | 12.0% | 11.0% | 8.0% | 24.0% | 18.0% | 13.0% | 15.0% | 11.0% | 6.0% | |
Core gross profit YoY CER (%)(%) | 6.0% | 9.0% | 0.0% | 10.0% | 11.0% | 10.0% | 26.0% | 21.0% | 17.0% | 18.0% | 11.0% | 7.0% | |
Reported (IFRS) gross profit ($M)($M) | 12,861 | 12,610 | 12,385 | 12,390 | 11,984 | 11,347 | 12,166 | 10,484 | 10,755 | 10,461 | 9,716 | 9,397 | |
Reported (IFRS) gross margin (%)(%) | 84.0% | 82.0% | 80.0% | 82.0% | 83.0% | 84.0% | |||||||
Core R&D expense ($M)($M)5 | -3,662 | -3,461 | -3,731 | -3,550 | -3,453 | -3,088 | -3,573 | -3,068 | -2,872 | -2,698 | -2,914 | -2,485 | |
Core R&D expense (% of total revenue)(%) | 24.0% | 23.0% | 24.0% | 23.0% | 24.0% | 23.0% | |||||||
Core R&D expense YoY actual (%)(%) | 6.0% | 12.0% | 4.0% | 16.0% | 20.0% | 14.0% | 23.0% | 23.0% | 12.0% | 17.0% | 15.0% | 5.0% | |
Core R&D expense YoY CER (%)(%) | 5.0% | 8.0% | 3.0% | 14.0% | 18.0% | 16.0% | 22.0% | 24.0% | 13.0% | 18.0% | 14.0% | 5.0% | |
Reported (IFRS) R&D expense ($M)($M) | -4,053 | -3,492 | -3,862 | -3,663 | -3,548 | -3,159 | -4,677 | -3,115 | -3,008 | -2,783 | -3,073 | -2,584 | |
Reported (IFRS) R&D expense (% of total revenue)(%) | 26.0% | 23.0% | 25.0% | 24.0% | 25.0% | 23.0% | |||||||
Core SG&A expense ($M)($M)7 | -4,050 | -3,859 | -4,453 | -3,822 | -3,802 | -3,457 | -4,275 | -3,605 | -3,735 | -3,413 | -4,034 | -3,355 | |
Core SG&A expense (% of total revenue)(%) | 26.0% | 25.0% | 29.0% | 25.0% | 26.0% | 25.0% | |||||||
Core SG&A expense YoY actual (%)(%) | 7.0% | 12.0% | 4.0% | 6.0% | 2.0% | 1.0% | 6.0% | 8.0% | 13.0% | 12.0% | 13.0% | 6.0% | |
Core SG&A expense YoY CER (%)(%) | 4.0% | 7.0% | 2.0% | 4.0% | 1.0% | 4.0% | 7.0% | 9.0% | 16.0% | 13.0% | 12.0% | 7.0% | |
Reported (IFRS) SG&A expense ($M)($M) | -5,651 | -4,920 | -5,492 | -5,085 | -4,864 | -4,492 | -5,410 | -5,143 | -4,929 | -4,495 | -5,371 | -4,800 | |
Reported (IFRS) SG&A expense (% of total revenue)(%) | 37.0% | 32.0% | 35.0% | 33.0% | 34.0% | 33.0% | |||||||
Core distribution expense ($M)($M) | -145 | -141 | -153 | -148 | -146 | -132 | -143 | -145 | -132 | -135 | -145 | -129 | |
Core other operating income & expense ($M)($M) | 152 | 189 | 101 | 96 | 71 | 115 | 101 | 24 | 60 | 65 | 107 | 70 | |
Core operating profit ($M)($M)7 | 5,158 | 5,352 | 4,098 | 4,993 | 4,584 | 4,803 | 4,199 | 4,318 | 4,101 | 4,310 | 2,752 | 3,545 | |
Core operating margin (% of total revenue)(%) | 34.0% | 35.0% | 26.0% | 33.0% | 32.0% | 35.0% | 28.0% | 32.0% | 32.0% | 34.0% | 22.9% | 30.8% | |
Core operating profit YoY actual (%)(%) | 12.0% | 11.0% | -2.0% | 16.0% | 12.0% | 11.0% | 53.0% | 22.0% | -4.0% | 9.0% | 5.0% | 4.0% | |
Core operating profit YoY CER (%)(%) | 10.0% | 12.0% | -5.0% | 13.0% | 14.0% | 12.0% | 58.0% | 27.0% | 1.0% | 15.0% | 6.0% | 9.0% | |
Reported (IFRS) operating profit ($M)($M) | 3,164 | 4,246 | 2,978 | 3,583 | 3,508 | 3,674 | 2,036 | 2,106 | 2,746 | 3,115 | 1,234 | 1,954 | |
Reported (IFRS) operating margin (%)(%) | 21.0% | 28.0% | 19.0% | 24.0% | 24.0% | 27.0% | 14.0% | 16.0% | 21.0% | 25.0% | 10.3% | 17.0% | |
Core adjustment — Total restructuring charges ($M)($M) | -100 | -60 | -57 | -79 | 21 | -122 | -100 | -705 | -154 | -195 | -115 | -124 | |
Core adjustment — Intangible asset amortisation & impairments ($M)($M) | -1,546 | -990 | -1,124 | -1,181 | -1,047 | -975 | -2,003 | -1,469 | -987 | -955 | -1,007 | -1,014 | |
Core EPS ($ per share)($)5 | 2.63 | 2.58 | 2.12 | 2.38 | 2.17 | 2.49 | 2.09 | 2.08 | 1.98 | 2.06 | 1.45 | 1.73 | |
Core EPS YoY actual (%)(%) | 21.0% | 4.0% | 1.0% | 14.0% | 10.0% | 21.0% | 44.0% | 20.0% | -8.0% | 7.0% | 5.0% | 4.0% | |
Core EPS YoY CER (%)(%) | 18.0% | 5.0% | -2.0% | 12.0% | 12.0% | 21.0% | 49.0% | 27.0% | -3.0% | 13.0% | 7.0% | 9.0% | |
Reported (IFRS) basic EPS ($ per share)($) | 1.61 | 1.99 | 1.50 | 1.64 | 1.58 | 1.88 | 0.97 | 0.92 | 1.24 | 1.41 | 0.62 | 0.89 | |
Core net finance expense ($M)($M) | -340 | -281 | -269 | -305 | -303 | -215 | -310 | -329 | -285 | -245 | -259 | -223 | |
Core income tax expense ($M)($M) | -731 | -1,058 | -543 | -1,002 | -911 | -714 | -640 | -753 | -741 | -867 | -242 | -624 | |
EBITDA ($M)($M)1 | 5,092 | 5,612 | 4,489 | 5,132 | 4,897 | 4,958 | 4,373 | 3,923 | 4,025 | 4,370 | 2,561 | 3,236 | |
Depreciation, amortisation & impairment added back in EBITDA ($M)($M) | 1,928 | 1,366 | 1,511 | 1,549 | 1,389 | 1,284 | 2,337 | 1,817 | 1,279 | 1,255 | 1,327 | 1,282 | |
FX sensitivity (+5% vs USD): EUR impact on annual Total Revenue ($M)($M)14 | 499 | 499 | 499 | -461 | -461 | -461 | -461 | 397 | 397 | 397 | 397 | 323 | |
Net intangible assets carrying value ($M)($M) | 37,723 | 37,846 | 37,925 | 37,177 | 39,426 | 38,089 | |||||||
Total inventories carrying value ($M)($M) | 6,932 | 6,557 | 6,467 | 5,288 | 5,667 | 5,424 | |||||||
Property, plant and equipment (PP&E) — net carrying value ($M)($M) | 13,615 | 12,962 | 11,637 | 10,252 | 9,630 | 9,402 | |||||||
Right-of-use (ROU) lease assets — net carrying value ($M)($M) | 2,685 | 1,741 | 1,592 | 1,395 | 1,203 | 1,100 | |||||||
Net debt ($M)($M)3 | 26,912 | 25,944 | 23,374 | 23,965 | 25,227 | 26,067 | 24,570 | 26,348 | 26,324 | 26,449 | 22,510 | 23,371 | |
Total cash, cash equivalents & current investments ($M)($M)2 | 4,968 | 7,675 | 5,741 | 8,182 | 7,108 | 5,395 | 5,654 | 4,930 | 7,076 | 8,021 | 5,962 | 5,115 | |
Cash and cash equivalents ($M)($M) | 4,893 | 7,560 | 5,711 | 8,143 | 7,058 | 5,230 | 5,488 | 4,797 | 6,916 | 7,841 | 5,840 | 4,871 | |
Other current fixed-income investments ($M)($M) | 75 | 115 | 30 | 39 | 50 | 165 | 166 | 133 | 160 | 180 | 122 | 244 | |
Total gross debt (loans, bonds, overdrafts & lease liabilities) ($M)($M)4 | -32,239 | -33,918 | -29,622 | -32,632 | -32,839 | -31,646 | -30,295 | -31,562 | -33,533 | -34,551 | -28,622 | -28,576 | |
Non-current loans & bonds ($M)($M) | -23,683 | -24,454 | -24,715 | -24,700 | -24,714 | -26,692 | -26,506 | -28,887 | -27,225 | -27,259 | -22,365 | -22,225 | |
Current portion of loans & bonds ($M)($M) | -2,859 | -4,567 | -2,460 | -4,461 | -4,461 | -2,010 | -2,007 | -12 | -2,018 | -4,593 | -4,614 | -4,857 | |
Lease liabilities ($M)($M) | -2,748 | -1,888 | -1,803 | -1,758 | -1,633 | -1,551 | -1,452 | -1,422 | -1,241 | -1,242 | -1,128 | -979 | |
Short-term borrowings & bank overdrafts ($M)($M) | -542 | -597 | -644 | -622 | -561 | -445 | -330 | -769 | -596 | -477 | -515 | -515 | |
Net financial derivatives fair value in Net Debt ($M)($M) | 359 | 299 | 507 | 485 | 504 | 184 | 71 | 284 | 133 | 81 | 150 | 90 | |
Net cash inflow from operating activities ($M)($M)7 | 2,865 | 3,359 | 2,342 | 5,134 | 3,386 | 3,713 | 2,907 | 3,383 | 3,085 | 2,486 | 2,380 | 3,114 | |
Net cash inflow before financing activities ($M)($M) | -47 | 1,567 | 896 | 3,133 | 1,278 | 2,460 | 1,726 | 1,869 | 213 | 73 | 1,303 | 1,893 | |
Movement in working capital & short-term provisions ($M)($M) | -438 | -1,000 | -1,201 | 835 | -345 | -426 | -350 | 41 | -129 | -455 | |||
Income tax paid ($M)($M) | -1,525 | -526 | -652 | -644 | -1,186 | -363 | -772 | -641 | -907 | -430 | -656 | -649 | |
Interest paid ($M)($M) | -189 | -441 | -247 | -446 | -201 | -422 | -238 | -492 | -242 | -341 | -255 | -343 | |
Purchase of property, plant and equipment (Capex) ($M)($M) | -763 | -547 | -1,036 | -686 | -659 | -429 | -708 | -417 | -382 | -417 | -525 | -319 | |
Purchase of intangible assets ($M)($M) | -2,342 | -991 | -251 | -1,040 | -1,264 | -540 | -247 | -941 | -286 | -1,188 | -421 | -560 | |
Dividends paid to shareholders ($M)($M) | -1 | -3,287 | -3 | -1,611 | -10 | -3,347 | -3 | -1,576 | -17 | -3,033 | -2 | -1,410 | |
U.S. Retail Sales — Pharmacies and Drug Stores, Seasonally Adjusted ($M)1 | |||||||||||||
U.S. Personal Consumption Expenditures — Health Care Services, SAAR ($B)($M) | 3,790 | 3,700 | 3,667 | 3,615 | 3,530 | 3,465 | 3,418 | 3,358 | 3,288 | 3,244 | 3,159 | 3,079 | |
Consolidated Total Revenue ($M)($M)19 | 15,384 | 15,288 | 15,503 | 15,191 | 14,457 | 13,588 | 14,891 | 13,565 | 12,938 | 12,679 | 12,024 | 11,492 | |
Total assets ($M)($M)8 | 115,833 | 114,074 | 112,422 | 104,035 | 104,340 | 101,119 | |||||||
Net cash inflow from operating activities ($M)($M)3 | 2,865 | 3,359 | 2,342 | 5,134 | 3,386 | 3,713 | 2,907 | 3,383 | 3,085 | 2,486 | 2,380 | 3,114 | |
Italic numbers are calculated by StockData from reported figures (hover for the formula). Numbers with a dotted underline are read from the text of earnings releases and presentations; hover to see the exact sentence. Tick a row to add it to the chart above (up to 8 lines).
Methodology and excluded metrics
- Fiscal calendar & IFRS reporting: AstraZeneca PLC (CIK 0000901832) reports under IFRS in millions of U.S. dollars ($M) with a fiscal year ending December 31 (FY2025 ended December 31, 2025; Q2 2026 ended June 30, 2026; monthly Total Voting Rights through September 30, 2026).
- Core operational & commercial KPIs (Groups 1–4) cover: (1) Revenue by stream (Product Sales $55,702M, Alliance Revenue $3,053M led by Enhertu $1,945M, Tezspire $630M, Beyfortus $284M & Datroway $49M, and Collaboration Revenue $701M in FY2025) and Regional Total Revenue across the US ($25,571M), Emerging Markets ($14,487M split into China $6,654M and Ex-China Emerging Markets $7,833M), Europe ($12,727M), and Established RoW ($5,954M) with published Actual YoY % and Constant Exchange Rate (CER) YoY % growth; (2) Product Sales across all 5 Therapy Areas (Oncology, CVRM, R&I, V&I/ID, Rare Disease) and 34 continuous medicines broken down by all 5 geographic regions (World, US, Emerging Markets, Europe, Established RoW); (3) U.S. Gross-to-Net (GTN) Sales Rebates, Chargebacks & Returns reconciliation (FY2025 Gross U.S. Product Sales of $47,385M less $23,941M total GTN deductions — including $13,963M Managed Care & Medicare, $5,113M Chargebacks, $2,527M Medicaid, $483M Cash Discounts, $149M Customer Returns, $99M Branded Prescription Drug Fee, and $1,607M Other — yielding $23,444M Net U.S. Product Sales), Global/US/China/Rare Disease rebate reserves, U.S. GTN sensitivity %, and Top 3 U.S. Wholesaler concentration (78% of U.S. trade receivables; #1 wholesaler $8,218M and #2 wholesaler $5,957M in FY2025); and (4) R&D Clinical Pipeline (183 total projects, 116 Phase II/III projects, 21 late-stage NMEs, and 15 regulatory approvals in Q2 2026), Clinical Trial Transparency, Research Animals, and U.S. FDA Inspections / Form 483 Observations / Recalls.
- Extended operational & financial KPIs (Groups 5–12) cover Core vs. Reported P&L & FX sensitivities (+5% impact of EUR, CNY, JPY, GBP, SEK on Total Revenue & Core Operating Profit), Individual Medicine Intangible Assets (C5 Soliris/Ultomiris $9,990M, Strensiq/Kanuma $5,375M, Alexion IPR&D $3,350M, Calquence $2,110M, Enhertu $2,188M, Baxdrostat $1,813M, Datroway $1,561M), Inventories by stage, PP&E by country, Provisions rollforward, Partner Payables to Daiichi Sankyo & Bond Avillion, Monthly Total Voting Rights (1,551,053,289 shares at Sep 2026), Net Debt ($26,912M at Q2 2026), Subsidiary & Statutory Entity self-disclosures (AstraZeneca UK Limited, MedImmune UK Limited, and the $9.63B AstraZeneca US 401(k) Plan from Form 11-K), Global Workforce (96,800 employees at FY2025), Share Plans (PSP/GRSP/RSP), Defined Benefit Pensions (UK, Sweden, Other), Access to Healthcare reach (108M people), Scope 1/2/3 GHG emissions, FRED industry benchmarks, and Consolidated Financial Statements (with Q1/Q3/Q4 backfill).
- Parent-only standalone financial statements in the UK Annual Report are prepared under FRS 101 (UK GAAP) on an annual-only basis for AstraZeneca PLC as a non-trading holding company ($0 product sales), so Consolidated − Standalone subtraction is not applicable under Bước 3. All values are strictly as published (with verbatim quotes on hover for text-extracted cells), plus period-splitting (Q2 = H1 − Q1; Q3 = 9M − H1; Q4 = FY − 9M) displayed in italic with the formula.
Not shown because recent periods are missing (325)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Enhertu (trastuzumab deruxtecan — direct product sales) — Worldwide product sales ($M) › Enhertu (trastuzumab deruxtecan — direct product sales) — Emerging Markets product sales ($M) › Enhertu (trastuzumab deruxtecan — direct product sales) — Emerging Markets YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Enhertu (trastuzumab deruxtecan — direct product sales) — Worldwide product sales ($M) › Enhertu (trastuzumab deruxtecan — direct product sales) — Emerging Markets product sales ($M) › Enhertu (trastuzumab deruxtecan — direct product sales) — Emerging Markets YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Enhertu (trastuzumab deruxtecan — direct product sales) — Worldwide product sales ($M) › Enhertu (trastuzumab deruxtecan — direct product sales) — Established RoW product sales ($M) › Enhertu (trastuzumab deruxtecan — direct product sales) — Established RoW YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Enhertu (trastuzumab deruxtecan — direct product sales) — Worldwide product sales ($M) › Enhertu (trastuzumab deruxtecan — direct product sales) — Established RoW product sales ($M) › Enhertu (trastuzumab deruxtecan — direct product sales) — Established RoW YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Truqap (capivasertib) — Worldwide product sales ($M) › Truqap (capivasertib) — Emerging Markets product sales ($M) › Truqap (capivasertib) — Emerging Markets YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Truqap (capivasertib) — Worldwide product sales ($M) › Truqap (capivasertib) — Emerging Markets product sales ($M) › Truqap (capivasertib) — Emerging Markets YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Truqap (capivasertib) — Worldwide product sales ($M) › Truqap (capivasertib) — Europe product sales ($M) › Truqap (capivasertib) — Europe YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Truqap (capivasertib) — Worldwide product sales ($M) › Truqap (capivasertib) — Europe product sales ($M) › Truqap (capivasertib) — Europe YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Truqap (capivasertib) — Worldwide product sales ($M) › Truqap (capivasertib) — Established RoW product sales ($M) › Truqap (capivasertib) — Established RoW YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Truqap (capivasertib) — Worldwide product sales ($M) › Truqap (capivasertib) — Established RoW product sales ($M) › Truqap (capivasertib) — Established RoW YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Faslodex (fulvestrant) — Worldwide product sales ($M) › Faslodex (fulvestrant) — Worldwide YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Faslodex (fulvestrant) — Worldwide product sales ($M) › Faslodex (fulvestrant) — Worldwide YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Faslodex (fulvestrant) — Worldwide product sales ($M) › Faslodex (fulvestrant) — US product sales ($M) › Faslodex (fulvestrant) — US YoY (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Faslodex (fulvestrant) — Worldwide product sales ($M) › Faslodex (fulvestrant) — US product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Faslodex (fulvestrant) — Worldwide product sales ($M) › Faslodex (fulvestrant) — Emerging Markets product sales ($M) › Faslodex (fulvestrant) — Emerging Markets YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Faslodex (fulvestrant) — Worldwide product sales ($M) › Faslodex (fulvestrant) — Emerging Markets product sales ($M) › Faslodex (fulvestrant) — Emerging Markets YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Faslodex (fulvestrant) — Worldwide product sales ($M) › Faslodex (fulvestrant) — Emerging Markets product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Faslodex (fulvestrant) — Worldwide product sales ($M) › Faslodex (fulvestrant) — Europe product sales ($M) › Faslodex (fulvestrant) — Europe YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Faslodex (fulvestrant) — Worldwide product sales ($M) › Faslodex (fulvestrant) — Europe product sales ($M) › Faslodex (fulvestrant) — Europe YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Faslodex (fulvestrant) — Worldwide product sales ($M) › Faslodex (fulvestrant) — Europe product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Faslodex (fulvestrant) — Worldwide product sales ($M) › Faslodex (fulvestrant) — Established RoW product sales ($M) › Faslodex (fulvestrant) — Established RoW YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Faslodex (fulvestrant) — Worldwide product sales ($M) › Faslodex (fulvestrant) — Established RoW product sales ($M) › Faslodex (fulvestrant) — Established RoW YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Faslodex (fulvestrant) — Worldwide product sales ($M) › Faslodex (fulvestrant) — Established RoW product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Faslodex (fulvestrant) — Worldwide product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Orpathys (savolitinib) — Worldwide product sales ($M) › Orpathys (savolitinib) — Worldwide YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Orpathys (savolitinib) — Worldwide product sales ($M) › Orpathys (savolitinib) — Worldwide YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Orpathys (savolitinib) — Worldwide product sales ($M) › Orpathys (savolitinib) — US product sales ($M) › Orpathys (savolitinib) — US YoY (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Orpathys (savolitinib) — Worldwide product sales ($M) › Orpathys (savolitinib) — US product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Orpathys (savolitinib) — Worldwide product sales ($M) › Orpathys (savolitinib) — Emerging Markets product sales ($M) › Orpathys (savolitinib) — Emerging Markets YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Orpathys (savolitinib) — Worldwide product sales ($M) › Orpathys (savolitinib) — Emerging Markets product sales ($M) › Orpathys (savolitinib) — Emerging Markets YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Orpathys (savolitinib) — Worldwide product sales ($M) › Orpathys (savolitinib) — Emerging Markets product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Orpathys (savolitinib) — Worldwide product sales ($M) › Orpathys (savolitinib) — Europe product sales ($M) › Orpathys (savolitinib) — Europe YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Orpathys (savolitinib) — Worldwide product sales ($M) › Orpathys (savolitinib) — Europe product sales ($M) › Orpathys (savolitinib) — Europe YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Orpathys (savolitinib) — Worldwide product sales ($M) › Orpathys (savolitinib) — Europe product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Orpathys (savolitinib) — Worldwide product sales ($M) › Orpathys (savolitinib) — Established RoW product sales ($M) › Orpathys (savolitinib) — Established RoW YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Orpathys (savolitinib) — Worldwide product sales ($M) › Orpathys (savolitinib) — Established RoW product sales ($M) › Orpathys (savolitinib) — Established RoW YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Orpathys (savolitinib) — Worldwide product sales ($M) › Orpathys (savolitinib) — Established RoW product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Orpathys (savolitinib) — Worldwide product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Iressa (gefitinib) — Worldwide product sales ($M) › Iressa (gefitinib) — Worldwide YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Iressa (gefitinib) — Worldwide product sales ($M) › Iressa (gefitinib) — Worldwide YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Iressa (gefitinib) — Worldwide product sales ($M) › Iressa (gefitinib) — US product sales ($M) › Iressa (gefitinib) — US YoY (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Iressa (gefitinib) — Worldwide product sales ($M) › Iressa (gefitinib) — US product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Iressa (gefitinib) — Worldwide product sales ($M) › Iressa (gefitinib) — Emerging Markets product sales ($M) › Iressa (gefitinib) — Emerging Markets YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Iressa (gefitinib) — Worldwide product sales ($M) › Iressa (gefitinib) — Emerging Markets product sales ($M) › Iressa (gefitinib) — Emerging Markets YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Iressa (gefitinib) — Worldwide product sales ($M) › Iressa (gefitinib) — Emerging Markets product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Iressa (gefitinib) — Worldwide product sales ($M) › Iressa (gefitinib) — Europe product sales ($M) › Iressa (gefitinib) — Europe YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Iressa (gefitinib) — Worldwide product sales ($M) › Iressa (gefitinib) — Europe product sales ($M) › Iressa (gefitinib) — Europe YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Iressa (gefitinib) — Worldwide product sales ($M) › Iressa (gefitinib) — Europe product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Iressa (gefitinib) — Worldwide product sales ($M) › Iressa (gefitinib) — Established RoW product sales ($M) › Iressa (gefitinib) — Established RoW YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Iressa (gefitinib) — Worldwide product sales ($M) › Iressa (gefitinib) — Established RoW product sales ($M) › Iressa (gefitinib) — Established RoW YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Iressa (gefitinib) — Worldwide product sales ($M) › Iressa (gefitinib) — Established RoW product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Iressa (gefitinib) — Worldwide product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Casodex (bicalutamide) — Worldwide product sales ($M) › Casodex (bicalutamide) — Worldwide YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Casodex (bicalutamide) — Worldwide product sales ($M) › Casodex (bicalutamide) — Worldwide YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Casodex (bicalutamide) — Worldwide product sales ($M) › Casodex (bicalutamide) — US product sales ($M) › Casodex (bicalutamide) — US YoY (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Casodex (bicalutamide) — Worldwide product sales ($M) › Casodex (bicalutamide) — US product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Casodex (bicalutamide) — Worldwide product sales ($M) › Casodex (bicalutamide) — Emerging Markets product sales ($M) › Casodex (bicalutamide) — Emerging Markets YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Casodex (bicalutamide) — Worldwide product sales ($M) › Casodex (bicalutamide) — Emerging Markets product sales ($M) › Casodex (bicalutamide) — Emerging Markets YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Casodex (bicalutamide) — Worldwide product sales ($M) › Casodex (bicalutamide) — Emerging Markets product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Casodex (bicalutamide) — Worldwide product sales ($M) › Casodex (bicalutamide) — Europe product sales ($M) › Casodex (bicalutamide) — Europe YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Casodex (bicalutamide) — Worldwide product sales ($M) › Casodex (bicalutamide) — Europe product sales ($M) › Casodex (bicalutamide) — Europe YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Casodex (bicalutamide) — Worldwide product sales ($M) › Casodex (bicalutamide) — Europe product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Casodex (bicalutamide) — Worldwide product sales ($M) › Casodex (bicalutamide) — Established RoW product sales ($M) › Casodex (bicalutamide) — Established RoW YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Casodex (bicalutamide) — Worldwide product sales ($M) › Casodex (bicalutamide) — Established RoW product sales ($M) › Casodex (bicalutamide) — Established RoW YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Casodex (bicalutamide) — Worldwide product sales ($M) › Casodex (bicalutamide) — Established RoW product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Casodex (bicalutamide) — Worldwide product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Arimidex (anastrozole) — Worldwide product sales ($M) › Arimidex (anastrozole) — Worldwide YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Arimidex (anastrozole) — Worldwide product sales ($M) › Arimidex (anastrozole) — Worldwide YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Arimidex (anastrozole) — Worldwide product sales ($M) › Arimidex (anastrozole) — US product sales ($M) › Arimidex (anastrozole) — US YoY (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Arimidex (anastrozole) — Worldwide product sales ($M) › Arimidex (anastrozole) — US product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Arimidex (anastrozole) — Worldwide product sales ($M) › Arimidex (anastrozole) — Emerging Markets product sales ($M) › Arimidex (anastrozole) — Emerging Markets YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Arimidex (anastrozole) — Worldwide product sales ($M) › Arimidex (anastrozole) — Emerging Markets product sales ($M) › Arimidex (anastrozole) — Emerging Markets YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Arimidex (anastrozole) — Worldwide product sales ($M) › Arimidex (anastrozole) — Emerging Markets product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Arimidex (anastrozole) — Worldwide product sales ($M) › Arimidex (anastrozole) — Europe product sales ($M) › Arimidex (anastrozole) — Europe YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Arimidex (anastrozole) — Worldwide product sales ($M) › Arimidex (anastrozole) — Europe product sales ($M) › Arimidex (anastrozole) — Europe YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Arimidex (anastrozole) — Worldwide product sales ($M) › Arimidex (anastrozole) — Europe product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Arimidex (anastrozole) — Worldwide product sales ($M) › Arimidex (anastrozole) — Established RoW product sales ($M) › Arimidex (anastrozole) — Established RoW YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Arimidex (anastrozole) — Worldwide product sales ($M) › Arimidex (anastrozole) — Established RoW product sales ($M) › Arimidex (anastrozole) — Established RoW YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Arimidex (anastrozole) — Worldwide product sales ($M) › Arimidex (anastrozole) — Established RoW product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Arimidex (anastrozole) — Worldwide product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — US product sales ($M) › Etcamah (launched Q2 2026) — US YoY (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — US product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — Emerging Markets product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — Europe product sales ($M) › Etcamah (launched Q2 2026) — Europe YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — Europe product sales ($M) › Etcamah (launched Q2 2026) — Europe YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — Europe product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — Established RoW product sales ($M) › Etcamah (launched Q2 2026) — Established RoW YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — Established RoW product sales ($M) › Etcamah (launched Q2 2026) — Established RoW YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — Established RoW product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Oncology — Worldwide product sales ($M) › Etcamah (launched Q2 2026) — Worldwide product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Wainua (eplontersen) — Worldwide product sales ($M) › Wainua (eplontersen) — Emerging Markets product sales ($M) › Wainua (eplontersen) — Emerging Markets YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Wainua (eplontersen) — Worldwide product sales ($M) › Wainua (eplontersen) — Emerging Markets product sales ($M) › Wainua (eplontersen) — Emerging Markets YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Wainua (eplontersen) — Worldwide product sales ($M) › Wainua (eplontersen) — Europe product sales ($M) › Wainua (eplontersen) — Europe YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Wainua (eplontersen) — Worldwide product sales ($M) › Wainua (eplontersen) — Europe product sales ($M) › Wainua (eplontersen) — Europe YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Worldwide YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Worldwide YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — US product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — US YoY (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — US product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Emerging Markets product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Emerging Markets YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Emerging Markets product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Emerging Markets YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Emerging Markets product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Europe product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Europe YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Europe product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Europe YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Europe product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Established RoW product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Established RoW YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Established RoW product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Established RoW YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Established RoW product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Andexxa / Ondexxya (andexanet alfa) — Worldwide product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Worldwide YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Worldwide YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Worldwide product sales ($M) › Bydureon (exenatide ER) — US product sales ($M) › Bydureon (exenatide ER) — US YoY (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Worldwide product sales ($M) › Bydureon (exenatide ER) — US product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Emerging Markets product sales ($M) › Bydureon (exenatide ER) — Emerging Markets YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Emerging Markets product sales ($M) › Bydureon (exenatide ER) — Emerging Markets YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Emerging Markets product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Europe product sales ($M) › Bydureon (exenatide ER) — Europe YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Europe product sales ($M) › Bydureon (exenatide ER) — Europe YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Europe product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Established RoW product sales ($M) › Bydureon (exenatide ER) — Established RoW YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Established RoW product sales ($M) › Bydureon (exenatide ER) — Established RoW YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Established RoW product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Bydureon (exenatide ER) — Worldwide product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Worldwide YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Worldwide YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Worldwide product sales ($M) › Onglyza (saxagliptin) — US product sales ($M) › Onglyza (saxagliptin) — US YoY (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Worldwide product sales ($M) › Onglyza (saxagliptin) — US product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Emerging Markets product sales ($M) › Onglyza (saxagliptin) — Emerging Markets YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Emerging Markets product sales ($M) › Onglyza (saxagliptin) — Emerging Markets YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Emerging Markets product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Europe product sales ($M) › Onglyza (saxagliptin) — Europe YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Europe product sales ($M) › Onglyza (saxagliptin) — Europe YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Europe product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Established RoW product sales ($M) › Onglyza (saxagliptin) — Established RoW YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Established RoW product sales ($M) › Onglyza (saxagliptin) — Established RoW YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Established RoW product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Onglyza (saxagliptin) — Worldwide product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Byetta (exenatide) — Worldwide product sales ($M) › Byetta (exenatide) — Worldwide YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Byetta (exenatide) — Worldwide product sales ($M) › Byetta (exenatide) — Worldwide YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Byetta (exenatide) — Worldwide product sales ($M) › Byetta (exenatide) — US product sales ($M) › Byetta (exenatide) — US YoY (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Byetta (exenatide) — Worldwide product sales ($M) › Byetta (exenatide) — US product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Byetta (exenatide) — Worldwide product sales ($M) › Byetta (exenatide) — Emerging Markets product sales ($M) › Byetta (exenatide) — Emerging Markets YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Byetta (exenatide) — Worldwide product sales ($M) › Byetta (exenatide) — Emerging Markets product sales ($M) › Byetta (exenatide) — Emerging Markets YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Byetta (exenatide) — Worldwide product sales ($M) › Byetta (exenatide) — Emerging Markets product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Byetta (exenatide) — Worldwide product sales ($M) › Byetta (exenatide) — Europe product sales ($M) › Byetta (exenatide) — Europe YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Byetta (exenatide) — Worldwide product sales ($M) › Byetta (exenatide) — Europe product sales ($M) › Byetta (exenatide) — Europe YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Byetta (exenatide) — Worldwide product sales ($M) › Byetta (exenatide) — Europe product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Byetta (exenatide) — Worldwide product sales ($M) › Byetta (exenatide) — Established RoW product sales ($M) › Byetta (exenatide) — Established RoW YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Byetta (exenatide) — Worldwide product sales ($M) › Byetta (exenatide) — Established RoW product sales ($M) › Byetta (exenatide) — Established RoW YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Byetta (exenatide) — Worldwide product sales ($M) › Byetta (exenatide) — Established RoW product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Byetta (exenatide) — Worldwide product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Atacand (candesartan) — Worldwide product sales ($M) › Atacand (candesartan) — Worldwide YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Atacand (candesartan) — Worldwide product sales ($M) › Atacand (candesartan) — Worldwide YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Atacand (candesartan) — Worldwide product sales ($M) › Atacand (candesartan) — US product sales ($M) › Atacand (candesartan) — US YoY (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Atacand (candesartan) — Worldwide product sales ($M) › Atacand (candesartan) — US product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Atacand (candesartan) — Worldwide product sales ($M) › Atacand (candesartan) — Emerging Markets product sales ($M) › Atacand (candesartan) — Emerging Markets YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Atacand (candesartan) — Worldwide product sales ($M) › Atacand (candesartan) — Emerging Markets product sales ($M) › Atacand (candesartan) — Emerging Markets YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Atacand (candesartan) — Worldwide product sales ($M) › Atacand (candesartan) — Emerging Markets product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Atacand (candesartan) — Worldwide product sales ($M) › Atacand (candesartan) — Europe product sales ($M) › Atacand (candesartan) — Europe YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Atacand (candesartan) — Worldwide product sales ($M) › Atacand (candesartan) — Europe product sales ($M) › Atacand (candesartan) — Europe YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Atacand (candesartan) — Worldwide product sales ($M) › Atacand (candesartan) — Europe product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Atacand (candesartan) — Worldwide product sales ($M) › Atacand (candesartan) — Established RoW product sales ($M) › Atacand (candesartan) — Established RoW YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Atacand (candesartan) — Worldwide product sales ($M) › Atacand (candesartan) — Established RoW product sales ($M) › Atacand (candesartan) — Established RoW YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Atacand (candesartan) — Worldwide product sales ($M) › Atacand (candesartan) — Established RoW product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Atacand (candesartan) — Worldwide product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Other Diabetes medicines — Worldwide product sales ($M) › Other Diabetes medicines — Worldwide YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Other Diabetes medicines — Worldwide product sales ($M) › Other Diabetes medicines — Worldwide YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Other Diabetes medicines — Worldwide product sales ($M) › Other Diabetes medicines — US product sales ($M) › Other Diabetes medicines — US YoY (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Other Diabetes medicines — Worldwide product sales ($M) › Other Diabetes medicines — US product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Other Diabetes medicines — Worldwide product sales ($M) › Other Diabetes medicines — Emerging Markets product sales ($M) › Other Diabetes medicines — Emerging Markets YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Other Diabetes medicines — Worldwide product sales ($M) › Other Diabetes medicines — Emerging Markets product sales ($M) › Other Diabetes medicines — Emerging Markets YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Other Diabetes medicines — Worldwide product sales ($M) › Other Diabetes medicines — Emerging Markets product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Other Diabetes medicines — Worldwide product sales ($M) › Other Diabetes medicines — Europe product sales ($M) › Other Diabetes medicines — Europe YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Other Diabetes medicines — Worldwide product sales ($M) › Other Diabetes medicines — Europe product sales ($M) › Other Diabetes medicines — Europe YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Other Diabetes medicines — Worldwide product sales ($M) › Other Diabetes medicines — Europe product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Other Diabetes medicines — Worldwide product sales ($M) › Other Diabetes medicines — Established RoW product sales ($M) › Other Diabetes medicines — Established RoW YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Other Diabetes medicines — Worldwide product sales ($M) › Other Diabetes medicines — Established RoW product sales ($M) › Other Diabetes medicines — Established RoW YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Other Diabetes medicines — Worldwide product sales ($M) › Other Diabetes medicines — Established RoW product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Other Diabetes medicines — Worldwide product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Worldwide product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — US product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Worldwide product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Emerging Markets product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Worldwide product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Europe product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Europe YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Worldwide product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Europe product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Europe YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Worldwide product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Europe product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Worldwide product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Established RoW product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Established RoW YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Worldwide product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Established RoW product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Established RoW YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Worldwide product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Established RoW product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) › Baxfendy (baxdrostat — launched Q2 2026) — Worldwide product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Tezspire (tezepelumab — direct product sales) — Worldwide product sales ($M) › Tezspire (tezepelumab — direct product sales) — Emerging Markets product sales ($M) › Tezspire (tezepelumab — direct product sales) — Emerging Markets YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Tezspire (tezepelumab — direct product sales) — Worldwide product sales ($M) › Tezspire (tezepelumab — direct product sales) — Emerging Markets product sales ($M) › Tezspire (tezepelumab — direct product sales) — Emerging Markets YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Saphnelo (anifrolumab) — Worldwide product sales ($M) › Saphnelo (anifrolumab) — Emerging Markets product sales ($M) › Saphnelo (anifrolumab) — Emerging Markets YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Saphnelo (anifrolumab) — Worldwide product sales ($M) › Saphnelo (anifrolumab) — Emerging Markets product sales ($M) › Saphnelo (anifrolumab) — Emerging Markets YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Airsupra (albuterol/budesonide) — Worldwide product sales ($M) › Airsupra (albuterol/budesonide) — Worldwide YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Airsupra (albuterol/budesonide) — Worldwide product sales ($M) › Airsupra (albuterol/budesonide) — Worldwide YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Airsupra (albuterol/budesonide) — Worldwide product sales ($M) › Airsupra (albuterol/budesonide) — Emerging Markets product sales ($M) › Airsupra (albuterol/budesonide) — Emerging Markets YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Airsupra (albuterol/budesonide) — Worldwide product sales ($M) › Airsupra (albuterol/budesonide) — Emerging Markets product sales ($M) › Airsupra (albuterol/budesonide) — Emerging Markets YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Worldwide YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Worldwide YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — US product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — US YoY (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — US product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Emerging Markets product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Emerging Markets YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Emerging Markets product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Emerging Markets YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Emerging Markets product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Europe product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Europe YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Europe product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Europe YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Europe product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Established RoW product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Established RoW YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Established RoW product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Established RoW YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Established RoW product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Bevespi Aerosphere (glycopyrrolate/formoterol) — Worldwide product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Worldwide YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Worldwide YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — US product sales ($M) › Daliresp / Daxas (roflumilast) — US YoY (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — US product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Emerging Markets product sales ($M) › Daliresp / Daxas (roflumilast) — Emerging Markets YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Emerging Markets product sales ($M) › Daliresp / Daxas (roflumilast) — Emerging Markets YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Emerging Markets product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Europe product sales ($M) › Daliresp / Daxas (roflumilast) — Europe YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Europe product sales ($M) › Daliresp / Daxas (roflumilast) — Europe YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Europe product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Established RoW product sales ($M) › Daliresp / Daxas (roflumilast) — Established RoW YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Established RoW product sales ($M) › Daliresp / Daxas (roflumilast) — Established RoW YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Established RoW product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Respiratory & Immunology (R&I) — Worldwide product sales ($M) › Daliresp / Daxas (roflumilast) — Worldwide product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Beyfortus (nirsevimab — direct product sales) — Worldwide product sales ($M) › Beyfortus (nirsevimab — direct product sales) — Europe product sales ($M) › Beyfortus (nirsevimab — direct product sales) — Europe YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Beyfortus (nirsevimab — direct product sales) — Worldwide product sales ($M) › Beyfortus (nirsevimab — direct product sales) — Europe product sales ($M) › Beyfortus (nirsevimab — direct product sales) — Europe YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Beyfortus (nirsevimab — direct product sales) — Worldwide product sales ($M) › Beyfortus (nirsevimab — direct product sales) — Established RoW product sales ($M) › Beyfortus (nirsevimab — direct product sales) — Established RoW YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Beyfortus (nirsevimab — direct product sales) — Worldwide product sales ($M) › Beyfortus (nirsevimab — direct product sales) — Established RoW product sales ($M) › Beyfortus (nirsevimab — direct product sales) — Established RoW YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › FluMist / Fluenz (influenza vaccine) — Worldwide product sales ($M) › FluMist / Fluenz (influenza vaccine) — Emerging Markets product sales ($M) › FluMist / Fluenz (influenza vaccine) — Emerging Markets YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › FluMist / Fluenz (influenza vaccine) — Worldwide product sales ($M) › FluMist / Fluenz (influenza vaccine) — Emerging Markets product sales ($M) › FluMist / Fluenz (influenza vaccine) — Emerging Markets YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › FluMist / Fluenz (influenza vaccine) — Worldwide product sales ($M) › FluMist / Fluenz (influenza vaccine) — Established RoW product sales ($M) › FluMist / Fluenz (influenza vaccine) — Established RoW YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › FluMist / Fluenz (influenza vaccine) — Worldwide product sales ($M) › FluMist / Fluenz (influenza vaccine) — Established RoW product sales ($M) › FluMist / Fluenz (influenza vaccine) — Established RoW YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Other Vaccines & Immune Therapies — Worldwide product sales ($M) › Other Vaccines & Immune Therapies — US product sales ($M) › Other Vaccines & Immune Therapies — US YoY (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Other Vaccines & Immune Therapies — Worldwide product sales ($M) › Other Vaccines & Immune Therapies — Europe product sales ($M) › Other Vaccines & Immune Therapies — Europe YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Other Vaccines & Immune Therapies — Worldwide product sales ($M) › Other Vaccines & Immune Therapies — Europe product sales ($M) › Other Vaccines & Immune Therapies — Europe YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Synagis (palivizumab) — Worldwide product sales ($M) › Synagis (palivizumab) — US product sales ($M) › Synagis (palivizumab) — US YoY (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — US product sales ($M) › Evusheld (tixagevimab/cilgavimab) — US YoY (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — US product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Emerging Markets product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Europe product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Europe YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Europe product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Europe YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Europe product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Established RoW product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Established RoW YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Established RoW product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Established RoW YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Established RoW product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Evusheld (tixagevimab/cilgavimab) — Worldwide product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Worldwide YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Worldwide YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — US product sales ($M) › Vaxzevria / COVID-19 Vaccine — US YoY (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — US product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Emerging Markets product sales ($M) › Vaxzevria / COVID-19 Vaccine — Emerging Markets YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Emerging Markets product sales ($M) › Vaxzevria / COVID-19 Vaccine — Emerging Markets YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Emerging Markets product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Europe product sales ($M) › Vaxzevria / COVID-19 Vaccine — Europe YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Europe product sales ($M) › Vaxzevria / COVID-19 Vaccine — Europe YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Europe product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Established RoW product sales ($M) › Vaxzevria / COVID-19 Vaccine — Established RoW YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Established RoW product sales ($M) › Vaxzevria / COVID-19 Vaccine — Established RoW YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Established RoW product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › Vaxzevria / COVID-19 Vaccine — Worldwide product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Worldwide YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Worldwide YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — US product sales ($M) › COVID-19 mAbs & vaccine combined — US YoY (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — US product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Emerging Markets product sales ($M) › COVID-19 mAbs & vaccine combined — Emerging Markets YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Emerging Markets product sales ($M) › COVID-19 mAbs & vaccine combined — Emerging Markets YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Emerging Markets product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Europe product sales ($M) › COVID-19 mAbs & vaccine combined — Europe YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Europe product sales ($M) › COVID-19 mAbs & vaccine combined — Europe YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Europe product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Established RoW product sales ($M) › COVID-19 mAbs & vaccine combined — Established RoW YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Established RoW product sales ($M) › COVID-19 mAbs & vaccine combined — Established RoW YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Established RoW product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) › COVID-19 mAbs & vaccine combined — Worldwide product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Rare Disease (Alexion) — Worldwide product sales ($M) › Other Rare Disease medicines — Worldwide product sales ($M) › Other Rare Disease medicines — Emerging Markets product sales ($M) › Other Rare Disease medicines — Emerging Markets YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Rare Disease (Alexion) — Worldwide product sales ($M) › Other Rare Disease medicines — Worldwide product sales ($M) › Other Rare Disease medicines — Emerging Markets product sales ($M) › Other Rare Disease medicines — Emerging Markets YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Rare Disease (Alexion) — Worldwide product sales ($M) › Other Rare Disease medicines — Worldwide product sales ($M) › Other Rare Disease medicines — Established RoW product sales ($M) › Other Rare Disease medicines — Established RoW YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Rare Disease (Alexion) — Worldwide product sales ($M) › Other Rare Disease medicines — Worldwide product sales ($M) › Other Rare Disease medicines — Established RoW product sales ($M) › Other Rare Disease medicines — Established RoW YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Rare Disease (Alexion) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Worldwide YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Rare Disease (Alexion) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Worldwide YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Rare Disease (Alexion) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — US product sales ($M) › Kanuma (sebelipase alfa) — US YoY (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Rare Disease (Alexion) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — US product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Rare Disease (Alexion) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Emerging Markets product sales ($M) › Kanuma (sebelipase alfa) — Emerging Markets YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Rare Disease (Alexion) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Emerging Markets product sales ($M) › Kanuma (sebelipase alfa) — Emerging Markets YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Rare Disease (Alexion) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Emerging Markets product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Rare Disease (Alexion) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Europe product sales ($M) › Kanuma (sebelipase alfa) — Europe YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Rare Disease (Alexion) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Europe product sales ($M) › Kanuma (sebelipase alfa) — Europe YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Rare Disease (Alexion) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Europe product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Rare Disease (Alexion) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Established RoW product sales ($M) › Kanuma (sebelipase alfa) — Established RoW YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Rare Disease (Alexion) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Established RoW product sales ($M) › Kanuma (sebelipase alfa) — Established RoW YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Rare Disease (Alexion) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Established RoW product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Rare Disease (Alexion) — Worldwide product sales ($M) › Kanuma (sebelipase alfa) — Worldwide product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Other Established / Legacy Medicines — Worldwide product sales ($M) › Other Established / Legacy Medicines — US product sales ($M) › Other Established / Legacy Medicines — US YoY (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Worldwide YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Worldwide YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — US product sales ($M) › Losec / Prilosec (omeprazole) — US YoY (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — US product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Emerging Markets product sales ($M) › Losec / Prilosec (omeprazole) — Emerging Markets YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Emerging Markets product sales ($M) › Losec / Prilosec (omeprazole) — Emerging Markets YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Emerging Markets product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Europe product sales ($M) › Losec / Prilosec (omeprazole) — Europe YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Europe product sales ($M) › Losec / Prilosec (omeprazole) — Europe YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Europe product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Established RoW product sales ($M) › Losec / Prilosec (omeprazole) — Established RoW YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Established RoW product sales ($M) › Losec / Prilosec (omeprazole) — Established RoW YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Established RoW product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Losec / Prilosec (omeprazole) — Worldwide product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Worldwide YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Worldwide YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — US product sales ($M) › Seroquel XR / IR (quetiapine) — US YoY (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — US product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Emerging Markets product sales ($M) › Seroquel XR / IR (quetiapine) — Emerging Markets YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Emerging Markets product sales ($M) › Seroquel XR / IR (quetiapine) — Emerging Markets YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Emerging Markets product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Europe product sales ($M) › Seroquel XR / IR (quetiapine) — Europe YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Europe product sales ($M) › Seroquel XR / IR (quetiapine) — Europe YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Europe product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Established RoW product sales ($M) › Seroquel XR / IR (quetiapine) — Established RoW YoY actual (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Established RoW product sales ($M) › Seroquel XR / IR (quetiapine) — Established RoW YoY CER (%)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Established RoW product sales ($M)
- Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý › Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) › Seroquel XR / IR (quetiapine) — Worldwide product sales ($M)
- Tầng mở rộng — Tài sản Vô hình theo Thuốc, Hàng tồn kho, Nhà máy (PP&E), Dự phòng Pháp lý & Thuế › Net intangible assets carrying value ($M) › Medicine intangible — MSD / Merck alliance option & co-promotion ($M)
- Bối cảnh Ngành Dược phẩm & Chi tiêu Y tế Mỹ (FRED / BLS / Census / BEA) › U.S. Retail Sales — Pharmacies and Drug Stores, Seasonally Adjusted ($M) › U.S. Retail Sales — Pharmacies and Drug Stores, Not Seasonally Adjusted ($M)
- Bối cảnh Ngành Dược phẩm & Chi tiêu Y tế Mỹ (FRED / BLS / Census / BEA) › U.S. Retail Sales — Pharmacies and Drug Stores, Seasonally Adjusted ($M)
- Epidemiology Data Tables (epidemiology_2024.xlsx & epidemiology_2026.xlsx) › Patient prevalence & incidence across Oncology / CVRM / R&I / Rare Disease (thiếu năm FY2025 giữa FY2024 và FY2026 nên đứt mạch năm theo Bước 5)
- Form 6-K Block Listing Six-Monthly Interim Reviews (2021–2026) › Unallotted share balances under employee share schemes (công bố 6 tháng/lần không đều kỳ quý/năm theo Bước 5)
Data updated 2026-10-28.
Every KPI on its own page
Full history, chart, sources and a citation for each metric
Tầng lõi — Cơ cấu Doanh thu (Product Sales, Alliance Revenue, Collaboration) & Doanh thu theo Khu vực Thị trường
Tầng lõi — Doanh thu Thuốc (Product Sales) theo Nhóm Bệnh & 34 Thuốc Chi tiết theo 5 Khu vực Địa lý
- Oncology — Worldwide product sales ($M) ($M)42 periods
- Cardiovascular, Renal & Metabolism (CVRM) — Worldwide product sales ($M) ($M)42 periods
- Respiratory & Immunology (R&I) — Worldwide product sales ($M) ($M)42 periods
- Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Worldwide product sales ($M) ($M)18 periods
- Rare Disease (Alexion) — Worldwide product sales ($M) ($M)20 periods
- Other Medicines (Established / Legacy Brands) — Worldwide product sales ($M) ($M)42 periods
Tầng lõi — Chiết khấu Gross-to-Net (GTN) tại Mỹ, Dự phòng Hoàn trả & Tập trung Nhà phân phối (US Wholesalers)
Tầng lõi — Tiến độ R&D, Pipeline Lâm sàng (Clinical Trials Appendix), Thử nghiệm & Chất lượng Nhà máy (FDA)
- Total projects in clinical development pipeline (count)11 periods
- Cumulative clinical trials with de-identified patient-level data shared (trials)4 periods
- Total animals used in preclinical research & regulatory testing (animals)4 periods
- U.S. FDA site inspections conducted across manufacturing & R&D network (inspections)4 periods
Tầng mở rộng — Hiệu quả Vận hành Core vs. Reported, Biên lợi nhuận, EBITDA & Độ nhạy Tỷ giá (FX)
Tầng mở rộng — Tài sản Vô hình theo Thuốc, Hàng tồn kho, Nhà máy (PP&E), Dự phòng Pháp lý & Thuế
- Net intangible assets carrying value ($M) ($M)21 periods
- Total inventories carrying value ($M) ($M)21 periods
- Property, plant and equipment (PP&E) — net carrying value ($M) ($M)21 periods
- Right-of-use (ROU) lease assets — net carrying value ($M) ($M)16 periods
- Total provisions (current + non-current) ($M) ($M)7 periods
- Collaboration partner payables — Daiichi Sankyo (Enhertu & Datroway) non-current ($M) ($M)2 periods
- Total undiscounted contractual maturity of financial liabilities ($M) ($M)6 periods
- Tax benefit from UK/Swedish IP Incentive (Patent Box) regimes ($M) ($M)5 periods
Tầng mở rộng — Cổ phiếu Lưu hành & Quyền Biểu quyết Hàng tháng (Form 6-K TVR), Nợ ròng (Net Debt) & Dòng tiền
Công ty con & Thực thể Pháp lý Tự công bố — AstraZeneca UK Ltd, MedImmune UK Ltd (UK GPGR) & Quỹ Hưu trí 401(k) Mỹ (Form 11-K)
Tầng mở rộng — Nhân sự Toàn cầu, Đãi ngộ Cổ phiếu (PSP/GRSP/RSP) & Quỹ Hưu trí Định mức (Defined Benefit)
Tầng mở rộng — Tiếp cận Y tế Toàn cầu (Access to Healthcare) & Môi trường / Bền vững (ESG Data Annex)
- Cumulative people reached through Access to Healthcare programmes (millions) (M)4 periods
- Total Scope 1 & Scope 2 (market-based) GHG emissions (tCO2e)5 periods
- Total Scope 3 value-chain GHG emissions (tCO2e)5 periods
- Total energy consumption across global sites & fleet (MWh)3 periods
- Total global water withdrawal across manufacturing & R&D sites (m3)5 periods